deltatrials
Terminated PHASE2 NCT00062504

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.

Sponsor: National Cancer Institute (NCI)

Conditions Anaplastic Astrocytoma Anaplastic Mixed Oligoastrocytoma Anaplastic Oligodendroglioma Glioblastoma Multiforme
Interventions Talampanel
Updated 7 times since 2017 Last updated: May 20, 2011 Started: Jul 31, 2003 Primary completion: Jan 31, 2006 Completion: Apr 30, 2006

Listed as NCT00062504, this PHASE2 trial focuses on Anaplastic Astrocytoma and Anaplastic Mixed Oligoastrocytoma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jan 2022 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Teva Branded Pharmaceutical Products R&D, Inc.
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.